Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Classic Hodgkin lymphoma (cHL) features a tumor microenvironment (TME) rich in inflammatory and immune cells.
• Other B-cell lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, also exhibit TMEs, but these differ significantly from cHL.
• The effectiveness of programmed cell death 1 (PD-1) pathway blockade therapies varies among patients with refractory or relapsed B-cell lymphomas and cHL.

Purpose of the Study:

• To highlight the distinct tumor microenvironments in various B-cell lymphomas.
• To underscore the variable response to PD-1 pathway blockade in refractory/relapsed lymphomas.
• To advocate for the development of novel assays for personalized therapy prediction.

Main Methods:

• Comparative analysis of tumor microenvironment characteristics across different lymphoma subtypes.
• Review of clinical outcomes for patients treated with PD-1 pathway blockade.
• Discussion of the need for innovative diagnostic tools.

Main Results:

• Tumor microenvironments in cHL, follicular lymphoma, and diffuse large B-cell lymphoma are demonstrably different.
• Significant variability exists in patient response to PD-1/PD-L1 blockade in refractory/relapsed settings.
• Current assays are insufficient to predict individual patient sensitivity or resistance to therapy.

Conclusions:

• Understanding the specific TME is crucial for B-cell lymphoma classification and treatment.
• Personalized medicine approaches are needed to optimize PD-1 pathway blockade efficacy.
• Development of novel molecular assays is essential for predicting treatment response in individual patients.